Deadline Approaches for ARS Pharmaceuticals Investors in Securities Suit

Faruqi & Faruqi, LLP, a leading national securities law firm, has reminded investors of an upcoming deadline to seek the role of lead plaintiff in a federal securities class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY). The deadline is October 5, 2026.

According to the press release, the lawsuit alleges that ARS Pharmaceuticals and its executives violated federal securities laws by making false and misleading statements and failing to disclose material adverse facts regarding the expected timeline for expanded insurance coverage of neffy through CVS Caremark. The complaint specifically points out that on June 24, 2026, ARS announced that no new commercial formulary additions or coverage decisions would be issued for neffy in the July 1, 2026 cycle, and that CVS Caremark had reserved its decision on expanded insurance coverage until January 2027. This news led to a significant drop in ARS's stock price, which fell $2.52, or 23.9%, to close at $8.02 per share on June 25, 2026, on unusually heavy trading volume.

Faruqi & Faruqi, LLP, is encouraging investors who purchased or acquired securities in ARS Pharmaceuticals between March 9, 2026, and June 24, 2026, to contact partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995 and maintains offices in New York, Pennsylvania, California, and Georgia.

Investors who believe they may be eligible to participate in the lawsuit are advised to review their trading records to confirm their purchases during the relevant period and to consider preserving all relevant documentation, including trade confirmations, account statements, and any communications related to their investment in ARS Pharmaceuticals. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members and directs and oversees the litigation on behalf of the putative class.

Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Participation in the case is not limited to those who seek appointment as lead plaintiff, and investors are encouraged to consult with Faruqi & Faruqi, LLP or other qualified securities counsel to better understand their rights and evaluate their legal options before the deadline passes.